Best Growth Stocks to Buy for September 21st

Zacks highlighted Petco (WOOF), Five Below (FIVE), and Oscar Health (OSCR) as Rank #1 Strong Buy growth stocks. Current-year consensus EPS estimates increased 26.3% for Petco, 15.2% for Five Below, and 194.9% for Oscar Health over the past 60 days. The article is analyst-driven stock-selection commentary and is unlikely to have broad market impact.

Analysis

This is a low-information, estimate-revision screen rather than an independently validated fundamental catalyst; it should not by itself move institutional positioning. The near-term reflex bid is most plausible in OSCR because small changes in medical-loss-ratio assumptions can produce outsized EPS revisions, but that same operating leverage makes the shares vulnerable to a single unfavorable utilization update. For WOOF and FIVE, revisions are more likely to be challenged by consumer-frequency data and gross-margin execution than by broad category growth.

Over the next 1-3 months, FIVE is the cleaner read-through on discretionary value demand: sustained positive comparable-sales commentary would pressure dollar-store and lower-income-exposed peers that are losing traffic, including DG and DLTR. Conversely, a soft back-to-school/holiday setup would expose the risk that EPS upgrades reflect cost control or lowered prior expectations rather than durable top-line acceleration. WOOF's relevant second-order issue is vendor funding and mix: improving merchandise margin without stable services/consumables retention would not warrant a multiple re-rating versus PETS or Chewy (CHWY).

OSCR has the most asymmetric 6-18 month setup, but only if enrollment growth converts without adverse selection and its administrative-cost ratio continues to decline. The market may be underestimating regulatory and risk-adjustment timing: policy or reimbursement changes can alter plan economics faster than reported revenue trends reveal. The contrarian view is that consensus upgrades across all three names may be late-cycle confirmation; estimate momentum is often least investable when valuation has already repriced the improvement.

Key Decisions for Investors

• Watch, do not chase, OSCR into its next earnings and membership/medical-cost update. Initiate a tactical long only if management reaffirms full-year medical-loss-ratio and administrative-cost guidance while raising membership or EBITDA outlook; use a 8-10% stop because an MLR miss can drive materially larger downside than the apparent estimate momentum implies.
• Express a 1-3 month consumer trade as long FIVE / short DG, sized beta-neutral, only after confirming positive comparable-sales and traffic trends. The thesis is that FIVE can gain value-oriented discretionary share without the consumables and shrink exposure weighing on DG; exit if FIVE comps decelerate or DG shows a sustained traffic recovery.
• Treat WOOF as an earnings-event watch rather than a standalone long. Upgrade to a position only if recurring-services growth, gross margin, and free-cash-flow conversion improve concurrently; a margin-only beat would be vulnerable to reversal and is insufficient to offset competitive pressure from CHWY and mass merchants.
• Avoid using AMZN, GOOG, or NVDA as AI-theme proxies for this signal. There is no demonstrated revenue linkage from the underlying information to those mega-cap earnings streams, so any associated move would be narrative-driven rather than a supported catalyst.